Tolerability of COVID-19 mRNA vaccines in patients with postural tachycardia syndrome: a cross-sectional study

Background: Postural tachycardia syndrome (POTS) is a form of autonomic dysregulation. There is increasing evidence that the etiology may be immune-mediated in a subgroup of patients. Patients with POTS often experience an exacerbation of their symptoms associated with (viral) infections and often fear the same symptom aggravation after vaccination. In this report we describe the tolerability of messenger ribonucleic acid (mRNA) vaccines against coronavirus disease 19 (COVID-19) and the consequences of a COVID-19 infection on POTS symptoms in our cohort of patients with neuropathic POTS. Methods: We conducted a standardized, checklist-based interview with 23 patients and recorded the acute side effects of mRNA vaccination, acute symptoms of COVID-19 infection as well as the effects of vaccination and COVID-19 infection on POTS symptoms. Results: Of all included patients, 20 patients received two mRNA vaccines without having had a previous COVID-19 infection, and five patients in total had suffered a COVID-19 infection. Of these, three had COVID-19 without and two after being vaccinated. No increased frequency of side effects after both doses of mRNA vaccines was observed. Six patients reported a mild and short-term aggravation of their POTS symptoms beyond the duration of acute vaccine side effects. All five patients who suffered a COVID-19 infection subsequently reported a pronounced and persistent exacerbation of POTS symptoms. Conclusions: Our observations suggest that mRNA vaccines are not associated with a higher frequency of acute side effects in patients with POTS. Symptom exacerbation as a consequence of mRNA vaccination seems to be less frequent and of shorter duration compared to patients who suffered a COVID-19 infection.

[1]  Shiliang Liu,et al.  Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapies , 2021, Reviews in medical virology.

[2]  Marc P. Waase,et al.  Autonomic dysfunction post–acute COVID-19 infection , 2021, HeartRhythm Case Reports.

[3]  M. Ståhlberg,et al.  Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know? , 2021, Journal of cardiovascular development and disease.

[4]  Edd Ricker,et al.  The Use of COVID-19 Vaccines in Patients with SLE , 2021, Current Rheumatology Reports.

[5]  C. Bassetti,et al.  An Unusual Case of Polyautoimmunity with Concomitant Presentation of Postural Tachycardia Syndrome, Antiphospholipid Syndrome and Hashimoto’s Thyroiditis , 2021, Clinical and Translational Neuroscience.

[6]  W. Z'Graggen,et al.  Leg pain in neuropathic postural tachycardia syndrome is associated with altered muscle membrane properties , 2021, Clinical Autonomic Research.

[7]  A. Ranjbar,et al.  How COVID‐19 can cause autonomic dysfunctions and postural orthostatic syndrome? A Review of mechanisms and evidence , 2021, Neurology and clinical neuroscience.

[8]  Jeroen J. Bax,et al.  Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 Syndrome , 2021, The American Journal of Medicine.

[9]  M. Miglis,et al.  Preparing for the long-haul: Autonomic complications of COVID-19 , 2021, Autonomic Neuroscience.

[10]  A. Lyne,et al.  COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine , 2021, BMJ Case Reports.

[11]  G. Shefer,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.

[12]  M. Arora,et al.  A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine , 2021, Cureus.

[13]  P. Anand,et al.  Review the safety of Covid-19 mRNA vaccines: a review , 2021, Patient Safety in Surgery.

[14]  G. Wallukat,et al.  Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms , 2021, Journal of Translational Autoimmunity.

[15]  S. Whitelaw,et al.  Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients , 2021, Immunologic Research.

[16]  M. Ståhlberg,et al.  Long-Haul Post–COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome , 2021, JACC: Case Reports.

[17]  S. Blitshteyn.  Is postural orthostatic tachycardia syndrome (POTS) a central nervous system disorder? , 2021, Journal of Neurology.

[18]  D. Klonoff,et al.  COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. , 2021, European review for medical and pharmacological sciences.

[19]  B. Grubb,et al.  Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies , 2021, Journal of clinical medicine.

[20]  W. Z'Graggen,et al.  Immunomodulatory treatment in postural tachycardia syndrome: A case series , 2020, European journal of neurology.

[21]  David S. Goldstein.  The possible association between COVID-19 and postural tachycardia syndrome , 2020, Heart Rhythm.

[22]  B. Grubb,et al.  New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection , 2020, The Journal of innovations in cardiac rhythm management.

[23]  T. Umapathi,et al.  Acute hyperhidrosis and postural tachycardia in a COVID-19 patient , 2020, Clinical Autonomic Research.

[24]  S. Jaradeh,et al.  A case report of postural tachycardia syndrome after COVID-19 , 2020, Clinical Autonomic Research.

[25]  M. Persson,et al.  Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome , 2020, Journal of the American Heart Association.

[26]  D. Goldstein,et al.  The extended autonomic system, dyshomeostasis, and COVID-19 , 2020, Clinical Autonomic Research.

[27]  S. Raj,et al.  Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. , 2020, The Canadian journal of cardiology.

[28]  B. Grubb,et al.  Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G‐Protein Coupled Receptor Autoantibodies , 2019, Journal of the American Heart Association.

[29]  A. Diedrich,et al.  The face of postural tachycardia syndrome – insights from a large cross‐sectional online community‐based survey , 2019, Journal of internal medicine.

[30]  W. Z'Graggen,et al.  Orthostatic Cognitive Dysfunction in Postural Tachycardia Syndrome After Rapid Water Drinking , 2019, Front. Neurosci..

[31]  A. Fedorowski.  Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management , 2018, Journal of internal medicine.

[32]  B. Goodman.  Evaluation of postural tachycardia syndrome (POTS) , 2018, Autonomic Neuroscience.

[33]  L. Stiles,et al.  Autoimmunity in postural orthostatic tachycardia syndrome: Current understanding , 2018, Autonomic Neuroscience.

[34]  Hongliang Li,et al.  Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome , 2018, Journal of the American Heart Association.

[35]  Y. Ando,et al.  Autoimmune postural orthostatic tachycardia syndrome , 2018, Annals of clinical and translational neurology.

[36]  B. Grubb,et al.  The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review , 2017, Scandinavian cardiovascular journal : SCJ.

[37]  O. Melander,et al.  Antiadrenergic autoimmunity in postural tachycardia syndrome , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[38]  S. Raj,et al.  Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance , 2015, Current Neurology and Neuroscience Reports.

[39]  Robert S Sheldon,et al.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. , 2015, Heart rhythm.

[40]  Hongliang Li,et al.  Autoimmune Basis for Postural Tachycardia Syndrome , 2014, Journal of the American Heart Association.

[41]  E. Benarroch.  Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. , 2012, Mayo Clinic proceedings.

[42]  Jens Jordan,et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome , 2011, Clinical Autonomic Research.

[43]  B. Grubb.  Postural tachycardia syndrome. , 2008, Circulation.

[44]  W. Shen,et al.  Postural orthostatic tachycardia syndrome: the Mayo clinic experience. , 2007, Mayo Clinic proceedings.

[45]  J. Stewart.  Chronic orthostatic intolerance and the postural tachycardia syndrome (POTS). , 2004, The Journal of pediatrics.